ENTA — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

8.84

Margin Of Safety %

Put/Call OI Ratio

1.62

EPS Next Q Diff

-0.18

EPS Last/This Y

1.96

EPS This/Next Y

-0.17

Price

13.77

Target Price

21.57

Analyst Recom

1.14

Performance Q

-8.75

Upside

-513.8%

Beta

0.94

Ticker: ENTA

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	ENTA	13.62	0.46	9.00	1078
2026-07-14	ENTA	13.11	0.46	9.00	1078
2026-07-15	ENTA	13.22	0.47	999.99	1088
2026-07-16	ENTA	13.16	0.50	0.73	1077
2026-07-17	ENTA	13.76	0.50	0.00	1111
2026-07-20	ENTA	13.17	0.29	999.99	525
2026-07-21	ENTA	13.39	0.56	999.99	635
2026-07-22	ENTA	13.06	0.64	999.99	666
2026-07-23	ENTA	12.93	1.35	999.99	956
2026-07-24	ENTA	12.76	1.48	999.99	1006
2026-07-27	ENTA	12.72	1.48	999.99	1006
2026-07-28	ENTA	12.62	1.48	5.19	1006
2026-07-29	ENTA	12.45	1.44	999.99	1027
2026-07-30	ENTA	13	1.45	0.40	1030
2026-07-31	ENTA	12.56	1.42	999.99	1044
2026-08-03	ENTA	12.97	1.65	999.99	1144
2026-08-04	ENTA	13.32	1.65	0.00	1144
2026-08-05	ENTA	13.23	1.62	6.00	1154
2026-08-07	ENTA	13.76	1.62	6.00	1154
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	ENTA	13.62	40.0	-	-1.88
2026-07-14	ENTA	13.10	40.0	-	-1.88
2026-07-15	ENTA	13.23	40.0	-	-1.88
2026-07-16	ENTA	13.17	40.0	-	-1.88
2026-07-17	ENTA	13.74	40.0	-	-1.88
2026-07-20	ENTA	13.15	40.0	-	-1.88
2026-07-21	ENTA	13.40	40.0	-	-1.88
2026-07-22	ENTA	13.04	40.0	-	-1.88
2026-07-23	ENTA	12.95	40.0	-	-1.88
2026-07-24	ENTA	12.75	40.0	-	-1.88
2026-07-27	ENTA	12.75	40.0	-	-1.88
2026-07-28	ENTA	12.62	40.0	-	-1.88
2026-07-29	ENTA	12.44	40.0	-	-1.88
2026-07-30	ENTA	12.97	40.0	-	-1.88
2026-07-31	ENTA	12.59	40.0	-	-1.88
2026-08-03	ENTA	12.95	40.0	-	-1.88
2026-08-04	ENTA	12.95	40.0	-	-1.88
2026-08-05	ENTA	13.23	40.0	-	-1.88
2026-08-06	ENTA	13.31	40.0	-	-1.88
2026-08-07	ENTA	13.77	40.0	-	-1.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	ENTA	0.00	0.16	9.36
2026-07-14	ENTA	0.00	0.16	9.36
2026-07-15	ENTA	0.00	0.16	9.36
2026-07-16	ENTA	0.00	0.16	9.36
2026-07-17	ENTA	0.00	0.16	9.36
2026-07-20	ENTA	0.00	-0.13	9.36
2026-07-21	ENTA	0.00	-0.13	9.36
2026-07-22	ENTA	0.00	-0.13	9.36
2026-07-23	ENTA	0.00	-0.13	9.36
2026-07-24	ENTA	0.00	-0.13	9.36
2026-07-27	ENTA	0.00	-0.11	8.84
2026-07-28	ENTA	0.00	-0.11	8.84
2026-07-29	ENTA	0.00	-0.11	8.84
2026-07-30	ENTA	0.00	-0.11	8.84
2026-07-31	ENTA	0.00	-0.11	8.84
2026-08-03	ENTA	0.00	-0.04	8.84
2026-08-04	ENTA	0.00	-0.04	8.84
2026-08-05	ENTA	0.00	-0.04	8.84
2026-08-06	ENTA	0.00	-0.04	8.84
2026-08-07	ENTA	0.00	-0.04	8.84
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.45

Avg. EPS Est. Current Quarter

-0.51

Avg. EPS Est. Next Quarter

-0.63

Insider Transactions

Institutional Transactions

-0.04

Beta

0.94

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.5

Max Drawdown 5-Year %

-95.6

Target Price

21.57

P/E

Forward P/E

PEG

P/S

5.79

P/B

3.43

P/Free Cash Flow

EPS

-2.59

Average EPS Est. Cur. Y

-1.88

EPS Next Y. (Est.)

-2.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-89.56

Relative Volume

0.86

Return on Equity vs Sector %

-80.5

Return on Equity vs Industry %

-64.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.06

EBIT Estimation

◆ ENTA Healthcare

$13.77

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

8/25

Volume

7/15

Valuation

10/20

TP/AR

4/10

Options

3/10

RSI

Range 1M

57%

Sup Dist

4.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

20/30

Estimates

2/20

Inst/Vol

1/15

Options

1/10

EPS Yr

40.2%

EPS NY

9.8%

52W%

68.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +56.6% upside

Quality

6/30

Valuation

12/30

Growth

16/25

Stability

5/10

LT Trend

3/5

Upside

+56.6%

Quality

ENTA — P/E HistoricalBiotechnology

Enanta Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 120

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ENTA

Latest News

—

Caricamento notizie per ENTA…

stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today

news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance

stock history ENTA – Enanta Pharmaceuticals Inc invest stock market

stock prices ENTA premarket after hours

ticker ENTA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ENTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y